This site is intended for healthcare professionals
Chronic Kidney Disease Learning Zone

Publication digest

Read time: 15 mins
Last updated:1st Nov 2021
Published:1st Nov 2021

The Publication Digests section of this Learning Zone provides simplified detail and graphical summaries of the latest published research on chronic kidney disease treatments.

The peer-reviewed article in this section describes clinical evidence for the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in the treatment of chronic kidney disease.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest